Bibliography
- Jemal A, Siegl R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300
- Gillatt D, Klotz L, Lawton C, Localised and Locally Advanced Prostate Cancer: who to Treat and How? Eur Urol Suppl 2007;6:334-43
- Hoffman RM. Screening for prostate cancer. N Engl J Med 2011;365:2013-19
- Tricoli JV, Schoenfeldt M, Conley BA. Detection of prostate cancer and predicting progression: current and future diagnostic markers. Clin Cancer Res 2004;10:3943-53
- Dasi F, Martinez-Rodes P, March JA, Real-time quantification of human telomerase reverse transcriptase in the plasma of patients with prostate cancer. Ann NY Acad Sci 2006;1075:204-10
- Dalle Carbonare L, Gasparetto A, Donatelli L, Telomerase mRNA detection in serum of patients with prostate cancer. Urol Oncol 2011; [Epub ahead of print]
- Available from: http://www.uroweb.org/gls/pdf/08%20Prostate%20Cancer_LR%20II.pdf [11 March 2012]
- Lledo SM, Garcia-Granero E, Dasi F, Real time quantification in plasma of human telomerase reverse transcriptase (hTERT) mRNA in patients with colorectal cancer. Colorectal Dis 2004;6:236-42
- Dasi F, Garcia-Granero E, Lledo S, Real-time quantification in plasma of human telomerase reverse transcriptase (hTERT) mRNA: a simple blood test to monitor disease in cancer patients. Lab Invest 2001;81:767-9
- Schroder FH, Hugosson J, Roobol MJ, Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8
- Roobol MJ, Steyerberg EW, Kranse R, A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol 2010;57:79-85
- Miura N, Osaki Y, Nagashima M, A novel biomarker TERTmRNA is applicable for early detection of hepatoma. BMC Gastroenterol 2010;10:46
- Shariat SH, Semjonow A, Lilja H, Tumor markers in prostate cancer I: blood-based markers. Acta Oncol 2011;50(Suppl 1):61-75
- Bastian PJ, Boorjian SA, Bossi A, High-risk prostate cancer: from definition to contemporary management. Eur Urol 2012;1096-106